A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GEP-NET / gastroenteropancreatic neuroendocrine tumors

[Related PubMed/MEDLINE]
Total Number of Papers: 106
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GEP-NET  (>> Co-occurring Abbreviation)
Long Form:   gastroenteropancreatic neuroendocrine tumors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Clinicopathologic profile of gastroenteropancreatic neuroendocrine neoplasms in a referral center of South India. GEP, MANECs, NEN, NSE, pan-CK
2022 CT-based radiomics to distinguish progressive from stable neuroendocrine liver metastases treated with somatostatin analogues: an explorative study. AP, CT, NELM, PD, PVP, SD, SSA
2022 Prevalence of malnutrition and nutrition-related complications in patients with gastroenteropancreatic neuroendocrine tumours. FFM, QoL
2022 Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET. HRQoL
2021 Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. OMI, PDCOs
2021 Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? ---
2021 Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. DpA, IA, PRRT
2021 Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities. GStT, LAR
2021 Ki-67 Proliferation Index Assessment in Gastroenteropancreatic Neuroendocrine Tumors by Digital Image Analysis With Stringent Case and Hotspot Level Concordance Requirements. DIA, ICC
10  2020 Apparent Diffusion Coefficient Values for Neuroendocrine Liver Metastases. ADC
11  2020 Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment? ASP, CI, HR, PFS, PRRT, SSR
12  2020 LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors. GLUT1, VHL-HIF
13  2020 Multiple endocrine neoplasia type 1 in patients with gastroenteropancreatic neuroendocrine tumors: An opportunity for early diagnosis and appropriate management. MEN1
14  2020 Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. SSAs, SST, SSTRs
15  2020 Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States. CI, HR, SI
16  2020 Tumor-non-tumor discrimination by a beta- detector for Radio Guided Surgery on ex-vivo neuroendocrine tumors samples. beta--RGS
17  2019 C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. CRP, GC, lncRNAs
18  2019 Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. CgA, MTT, OS, panNET, PFS, SSA, SSTR
19  2019 Multiple endocrine neoplasia type 1 in Poland: a two-centre experience. MEN1, PA, PHP
20  2019 Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. LM, OS, pNET, SB-NET
21  2019 [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy]. NET
22  2019 [Modern sonographic imaging of abdominal neuroendocrine tumors]. CEUS, CT, MRI
23  2018 Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context. GEP-NETs, MCDA, SSAs
24  2018 Arachidonic acid-induced Ca2+ entry and migration in a neuroendocrine cancer cell line. AA
25  2018 Comparison of Monitor-Image and Printout-Image Methods in Ki-67 Scoring of Gastroenteropancreatic Neuroendocrine Tumors. MIM, PIM
26  2018 Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. 5-HIAA, BIS, BIS, CS, HADS, HRQoL
27  2018 Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. GEP-NETs, MD, NETs, PhA
28  2018 Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A. IDC, NSE, SSTR-2A, TS
29  2018 Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. ---
30  2018 Risk factors associated with gastroenteropancreatic neuroendocrine tumors in a cohort of 2.3 million Israeli adolescents. BMI, CI, FSU, HR, SES
31  2018 Supplementation of Vitamin D Deficiency in Patients with Neuroendocrine Tumors Using Over-the-Counter Vitamin D3 Preparations. VitD
32  2018 The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. ---
33  2018 The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. OS, PFS, PRRT, SSA
34  2018 Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. JIS, MetS
35  2017 Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. NETs
36  2017 Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework. ASCO, ESMO, ESMO-MCBS, NHB, NHB-ASCO-F
37  2017 Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. SSTR, SSTR2a
38  2017 Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience. IHC, MANEC, NET
39  2017 Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. GEP-NETs, MCDA, SSA, WW
40  2017 Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). CNV, GLO1
41  2017 Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. CXCR4, PET/CT, SSTR
42  2017 Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up. MEN1
43  2017 Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. GEP-NEN, LAR, SSTRs
44  2017 [Interpretation and evaluation of the American Joint committee on Cancer (AJCC) 8th Edition Staging System for patients with gastroenteropancreatic neuroendocrine tumors]. AJCC, ENETS
45  2016 Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors. ---
46  2016 Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. CT, GEP-NETs, GLP-1R, MRI, PET, SRS, SSTR
47  2016 Gastroenteropancreatic neuroendocrine tumours: an overview. ---
48  2016 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. GEP-NETs, GI, NEC
49  2016 Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance. ---
50  2016 Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India. CECT, MEN1, NFT, PA, PHPT
51  2016 Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. CT, F-FDG, PRRT, SSTR
52  2016 Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study. MUST
53  2016 Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. GH, IGF-1
54  2016 Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. HRQoL
55  2016 Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. PRRT
56  2015 Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders. CgA, CR, OS, PD, PFS, PR, SD
57  2015 ⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay. ---
58  2014 Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. NET, PRRT
59  2014 Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. NE, non-GEP-NET
60  2014 May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate. BM, BTRT, PRRT, VAS
61  2014 Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. CE-MRI, DW-MRI, PRRT
62  2014 Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. PRRT
63  2014 Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation. IHC, SSTR
64  2014 Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET). ---
65  2014 [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. IA, sst2
66  2014 [Gastroenteropancreatic endocrine tumors]. CT, MRI, PET-CT
67  2014 [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy]. ---
68  2013 Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. CTCAE, DTPA, GFR, PRRT
69  2013 Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. BM, CgA, NSE, OS, PRRT, TTP
70  2013 Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor. ---
71  2013 Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. PFS, PRRT
72  2013 Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. LAR, SSA
73  2013 Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. ---
74  2013 [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors]. MANEC, NEC
75  2012 Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. CgA
76  2012 Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. ---
77  2012 Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. CAM, Hsp90
78  2012 Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy. BS
79  2012 Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. MEN1
80  2012 Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. ---
81  2012 The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET). CT, GEP-NETS
82  2012 [Results of multiple endocrine neoplasia type 1 in Japan from a multicenter database]. MEN1
83  2012 [Surgical prognostic factors of gastroenteropancreatic neuroendocrine tumors (GEP NET)]. ---
84  2011 Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. IHC, SRS, SST, SSTRs
85  2011 Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors. ---
86  2011 Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? CgA, PP, RECIST
87  2011 Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. ABHD14B
88  2011 Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. IRS, SSTR
89  2011 Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. MEN1
90  2010 mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. mTOR, p-4EBP1, p-eIF4E, pS6K
91  2010 [Gastroenteropatic neuroendocrine tumors: multidisciplinary approach in therapy]. PRRT
92  2009 Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. CgA, NETs, ROC
93  2009 Diagnostic pitfalls in digestive neuroendocrine tumours. 5-HIAA
94  2009 Locoregional and radioisotopic targeted treatment of neuroendocrine tumours. MIBG, PRRT
95  2009 Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction. ---
96  2009 Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story? 5-FU
97  2008 Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors. ---
98  2008 [Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)]. ---
99  2007 Peptide receptor expression in GEP-NET. ---
100  2007 The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET). 5-HTP, FDG, PET